These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 8823511)
21. The determination of metabolite M17 and its meaning for immunosuppressive cyclosporin therapy. Khoschsorur G; Auer T; Lanzer G; Petritsch P; Holzer H; Tscheliessnigg KH Angiology; 1998 Apr; 49(4):307-14. PubMed ID: 9555934 [TBL] [Abstract][Full Text] [Related]
22. Ketoconazole alters cyclosporine pharmacokinetic profile and may predispose to acute rejection. Dominguez J; Kompatzki A; Foradori A; Norambuena R Transplant Proc; 2003 Nov; 35(7):2522-3. PubMed ID: 14612002 [TBL] [Abstract][Full Text] [Related]
23. Enhanced oral cyclosporine absorption with water-soluble vitamin E early after liver transplantation. Pan SH; Lopez RR; Sher LS; Hoffman AL; Podesta LG; Makowka L; Rosenthal P Pharmacotherapy; 1996; 16(1):59-65. PubMed ID: 8700793 [TBL] [Abstract][Full Text] [Related]
24. Effect of streptozotocin-induced diabetes on cyclosporin A disposition in rats. Ogata M; Iizuka Y; Murata R; Hikichi N Biol Pharm Bull; 1996 Dec; 19(12):1586-90. PubMed ID: 8996644 [TBL] [Abstract][Full Text] [Related]
25. Evolution of the therapeutic drug monitoring of cyclosporine. Citterio F Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378 [TBL] [Abstract][Full Text] [Related]
26. A nomogram for predicting optimal dosage of cyclosporine in renal transplant patients: taking physiological factors into consideration for regimen during immunosuppressive therapy. Shibata N; Hoshino N; Minouchi T; Yamaji A Biol Pharm Bull; 1995 Oct; 18(10):1423-9. PubMed ID: 8593449 [TBL] [Abstract][Full Text] [Related]
27. Effect of non-insulin dependent diabetes on cyclosporin A disposition in Goto-Kakizaki (GK) rats. Ogata M; Uchimura T; Iizuka Y; Murata R; Suzuki S; Toyota T; Hikichi N Biol Pharm Bull; 1997 Sep; 20(9):1026-9. PubMed ID: 9331992 [TBL] [Abstract][Full Text] [Related]
28. Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone. Jin M; Shimada T; Yokogawa K; Nomura M; Kato Y; Tsuji A; Miyamoto K Int J Pharm; 2006 Feb; 309(1-2):81-6. PubMed ID: 16384676 [TBL] [Abstract][Full Text] [Related]
29. Cyclosporin A-loaded poly(ethylene glycol)-b-poly(d,l-lactic acid) micelles: preparation, in vitro and in vivo characterization and transport mechanism across the intestinal barrier. Zhang Y; Li X; Zhou Y; Fan Y; Wang X; Huang Y; Liu Y Mol Pharm; 2010 Aug; 7(4):1169-82. PubMed ID: 20540526 [TBL] [Abstract][Full Text] [Related]
30. Effect of serum triglyceride concentration on the fluctuation of whole blood concentration of cyclosporin A in patients. Nakamura T; Kakumoto M; Sakaeda T; Nagahiro K; Ohmichi R; Yamashita K; Nishiguchi K; Hirai M; Okumura K Biol Pharm Bull; 2001 Jun; 24(6):683-7. PubMed ID: 11411559 [TBL] [Abstract][Full Text] [Related]
31. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. Lam H; Jeffery J; Sitar DS; Aoki FY Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586 [TBL] [Abstract][Full Text] [Related]
32. Characterization of new oxidation products of 9H-carbazole and structure related compounds by biphenyl-utilizing bacteria. Waldau D; Methling K; Mikolasch A; Schauer F Appl Microbiol Biotechnol; 2009 Jan; 81(6):1023-31. PubMed ID: 18836714 [TBL] [Abstract][Full Text] [Related]
33. Brain cyclosporin A levels are determined by ontogenic regulation of mdr1a expression. Goralski KB; Acott PD; Fraser AD; Worth D; Sinal CJ Drug Metab Dispos; 2006 Feb; 34(2):288-95. PubMed ID: 16303871 [TBL] [Abstract][Full Text] [Related]
34. Inhibition of brush border dipeptidase with cilastatin reduces toxic accumulation of cyclosporin A in kidney proximal tubule epithelial cells. Pérez M; Castilla M; Torres AM; Lázaro JA; Sarmiento E; Tejedor A Nephrol Dial Transplant; 2004 Oct; 19(10):2445-55. PubMed ID: 15252165 [TBL] [Abstract][Full Text] [Related]
35. Effect of etretinate on cyclosporin metabolism in vitro. Webber IR; Back DJ Br J Dermatol; 1993 Jan; 128(1):42-4. PubMed ID: 8427820 [TBL] [Abstract][Full Text] [Related]
36. [Relative bioavailability of cyclosporine A-loaded hydroxypropyl methylcellulose phthalate nanoparticles for oral administration in rats]. Wang XQ; Dai JD; Zhang Q; Zhang T; Xia GM Yao Xue Xue Bao; 2004 Jun; 39(6):463-6. PubMed ID: 15491107 [TBL] [Abstract][Full Text] [Related]
37. Cell-free biosynthesis of cyclosporin A and analogues. Kleinkauf H; Dittmann J; Lawen A Biomed Biochim Acta; 1991; 50(10-11):S219-24. PubMed ID: 1820050 [TBL] [Abstract][Full Text] [Related]
38. Biotransformation of (-)-(R)-α-phellandrene: antimicrobial activity of its major metabolite. İşcan G; Kirimer N; Demirci F; Demirci B; Noma Y; Başer KH Chem Biodivers; 2012 Aug; 9(8):1525-32. PubMed ID: 22899613 [TBL] [Abstract][Full Text] [Related]
39. Evaluation and comparison of therapeutic monitoring of whole-blood levels of cyclosporin A and its metabolites in renal transplantation by HPLC and RIA methods. Safarcík K; Brozmanová H; Bartos V; Jegorov A; Grundmann M Clin Chim Acta; 2001 Aug; 310(2):165-71. PubMed ID: 11498082 [TBL] [Abstract][Full Text] [Related]
40. [Critical analysis of the immunosuppressive activity and of the toxicity of cyclosporine metabolites]. Garraffo R Therapie; 1992; 47(4):311-7. PubMed ID: 1494794 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]